Study of DF6215 in Patients with Advanced Solid Tumors
A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors
Sponsor: Dragonfly Therapeutics
Listed as NCT06108479, this PHASE1 trial focuses on Solid Tumor Cancer and Solid Tumor, Adult and remains actively recruiting participants. Sponsored by Dragonfly Therapeutics, it has been updated 8 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Apr 2025 — Present [monthly]
Recruiting PHASE1
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Feb 2024 — May 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Feb 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Dragonfly Therapeutics
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Bordeaux, France , Dijon, France , Frankston, Australia , Los Angeles, United States , Marseille, France , Nashville, United States , New York, United States , Orange, United States , Paris, France and 8 more locations